{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:46:52Z","timestamp":1784562412572,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to investigate a\u00a0first-site-metastasis pattern (FSMP) in unresectable stage\u00a0III NSCLC after concurrent chemoradiotherapy (cCRT) with or without immune checkpoint inhibition (ICI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We defined three patient subgroups according to the year of initial multimodal treatment: A\u00a0(2011\u20132014), B\u00a0(2015\u20132017) and C\u00a0(2018\u20132020). Different treatment-related parameters were analyzed. Observed outcome parameters were brain metastasis-free survival (BMFS), extracranial distant metastasis-free survival (ecDMFS) and distant metastasis-free survival (DMFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>136 patients treated between 2011 and 2020 were included with \u2265\u202f60.0\u202fGy total dose and concurrent chemotherapy (cCRT); thirty-six (26%) received ICI. Median follow-up was 49.7 (range:0.7\u2013126.1), median OS 31.2 (95% CI:16.4\u201330.3) months (23.4 for non-ICI vs not reached for ICI patients, <jats:italic>p<\/jats:italic>\u202f=\u20090.001).<\/jats:p>\n                <jats:p>Median BMFS\/ecDMFS\/DMFS in subgroups\u00a0A, B and\u00a0C was 14.9\/16.3\/14.7 months, 20.6\/12.9\/12.7 months and not reached (NR)\/NR\/36.4 months (<jats:italic>p<\/jats:italic>\u202f=\u20090.004\/0.001\/0.016).<\/jats:p>\n                <jats:p>For cCRT+ICI median BMFS was 53.1 vs. 19.1 months for cCRT alone (<jats:italic>p<\/jats:italic>\u202f=\u20090.005). Median ecDMFS achieved 55.2 vs. 17.9 (<jats:italic>p<\/jats:italic>\u202f=\u20090.003) and median DMFS 29.5 (95% CI: 1.4\u201357.6) vs 14.93 (95% CI:10.8\u201319.0) months (<jats:italic>p<\/jats:italic>\u202f=\u20090.031), respectively.<\/jats:p>\n                <jats:p>Multivariate analysis showed that age over 65 (HR:1.629; <jats:italic>p<\/jats:italic>\u202f=\u20090.036), GTV \u2265\u202f78\u202fcc (HR: 2.100; <jats:italic>p<\/jats:italic>\u202f=\u20090.002) and V20 \u2265\u202f30 (HR: 2.400; <jats:italic>p<\/jats:italic>\u202f=\u20090.002) were negative prognosticators for BMFS and GTV \u2265\u202f78\u202fcc for ecDMFS (HR: 1.739; <jats:italic>p<\/jats:italic>\u202f=\u20090.027).<\/jats:p>\n                <jats:p>After onset of brain metastasis (BM), patients survived 13.3 (95% CI: 6.4\u201320.2) months and 8.6\u00a0months (95% CI: 1.6\u201315.5) after extracranial-distant-metastasis (ecDM). Patients with ecDM as FSMP reached significantly worse overall survival of 22.1 (range:14.4\u201329.8) vs. 40.1 (range:18.7\u201361.3) months (<jats:italic>p<\/jats:italic>\u202f=\u20090.034) in the rest of cohort. In contrast, BM as FSMP had no impact on OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This retrospective analysis of inoperable stage\u00a0III NSCLC patients revealed that age over 65, V20 \u2265\u202f30 and GTV \u2265\u202f78\u202fcc were prognosticators for BMFS and GTV \u2265\u202f78\u202fcc for ecDMFS. ICI treatment led to a\u00a0significant improvement of BMFS, ecDMFS and DMFS. ecDM as FSMP was associated with significant deterioration of OS, whereas BM as FSMP was not.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-023-02175-6","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T13:01:43Z","timestamp":1700226103000},"page":"614-623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["First-site-metastasis pattern in patients with inoperable stage\u00a0III NSCLC treated with concurrent chemoradiotherapy with or without immune check-point inhibition: a\u00a0retrospective analysis"],"prefix":"10.1007","volume":"200","author":[{"given":"Kerstin","family":"Hofstetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-1202","authenticated-orcid":false,"given":"Julian","family":"Taugner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00e4smann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Mansoorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Fl\u00f6rsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuka","family":"Eze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Reinmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farkhad","family":"Manapov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"issue":"1","key":"2175_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Fuchs\u00a0HE et\u00a0al (2021) Statistics, 2021. CA: a\u00a0cancer journal for clinicians. Cancer 71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"Cancer"},{"issue":"9","key":"2175_CR2","doi-asserted-by":"publisher","first-page":"5077","DOI":"10.21873\/anticanres.13701","volume":"39","author":"L K\u00e4smann","year":"2019","unstructured":"K\u00e4smann\u00a0L, Taugner\u00a0J, Eze\u00a0C et\u00a0al (2019) Performance Status and Its Changes Predict Outcome for Patients With Inoperable Stage\u00a0III NSCLC Undergoing Multimodal Treatment. Anticancer Res 39(9):5077\u20135081. https:\/\/doi.org\/10.21873\/anticanres.13701","journal-title":"Anticancer Res"},{"issue":"5","key":"2175_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.21037\/tlcr.2019.09.19","volume":"8","author":"J Taugner","year":"2019","unstructured":"Taugner\u00a0J, K\u00e4smann\u00a0L, Eze\u00a0C et\u00a0al (2019) Survival score to characterize prognosis in inoperable stage\u00a0III NSCLC after chemoradiotherapy. Transl Lung Cancer Res 8(5):593\u2013604. https:\/\/doi.org\/10.21037\/tlcr.2019.09.19","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2175_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13014-020-01590-8","volume":"15","author":"J Taugner","year":"2020","unstructured":"Taugner\u00a0J, Eze\u00a0C, K\u00e4smann\u00a0L et al (2020) Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage\u00a0III non-small cell lung cancer. Radiat Oncol 15(1):148. https:\/\/doi.org\/10.1186\/s13014-020-01590-8","journal-title":"Radiat Oncol"},{"key":"2175_CR5","doi-asserted-by":"crossref","unstructured":"(1995) Chemotherapy in non-small cell lung cancer: a\u00a0meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ : British Medical Journal 311(7010): 899\u2013909","DOI":"10.1136\/bmj.311.7010.899"},{"key":"2175_CR6","doi-asserted-by":"publisher","unstructured":"Remon J, Soria J\u2011C, Peters S (2021) Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Annals of oncology : official journal of the European Society for Medical Oncology 32(12): 1637\u20131642. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1994","DOI":"10.1016\/j.annonc.2021.08.1994"},{"issue":"20","key":"2175_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia\u00a0SJ, Villegas\u00a0A, Daniel\u00a0D et al (2017) Durvalumab after Chemoradiotherapy in Stage\u00a0III Non-Small-Cell Lung Cancer. N\u00a0Engl J Med 377(20):1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"issue":"12","key":"2175_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel\u00a0DR, Faivre-Finn\u00a0C, Gray\u00a0JE et al (2022) Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage\u00a0III Non-Small-Cell Lung Cancer. J\u00a0Clin Oncol 40(12):1301\u20131311. https:\/\/doi.org\/10.1200\/JCO.21.01308","journal-title":"J Clin Oncol"},{"key":"2175_CR9","doi-asserted-by":"publisher","unstructured":"Rosset M, Reifegerste D, Baumann E et\u00a0al. (2019) Langzeittrends beim Krebsinformationsdienst (KID) des Deutschen Krebsforschungszentrums (DKFZ) : Eine Analyse der Anfragen von Patientinnen und Patienten sowie Angeh\u00f6rigen von 1992 bis 2016 (Trends in cancer information services over 25\u00a0years : An analysis of inquiries from patients and relatives made to the Cancer Information Service of the German Cancer Research Center from 1992to 2016). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 62(9): 1120\u20131128. https:\/\/doi.org\/10.1007\/s00103-019-02996-w","DOI":"10.1007\/s00103-019-02996-w"},{"issue":"3","key":"2175_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2217\/fon-2021-0795","volume":"18","author":"W Li","year":"2022","unstructured":"Li\u00a0W, Jiang\u00a0J, Huang\u00a0L et al (2022) Efficacy of PD-1\/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials. Future Oncol 18(3):403\u2013412. https:\/\/doi.org\/10.2217\/fon-2021-0795","journal-title":"Future Oncol"},{"key":"2175_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","volume":"133","author":"S Peters","year":"2019","unstructured":"Peters\u00a0S, Felip\u00a0E, Dafni\u00a0U et al (2019) Safety evaluation of nivolumab added concurrently to radiotherapy in a\u00a0standard first line chemo-radiotherapy regimen in stage\u00a0III non-small cell lung cancer-The ETOP NICOLAS trial. Lung Cancer 133:83\u201387. https:\/\/doi.org\/10.1016\/j.lungcan.2019.05.001","journal-title":"Lung Cancer"},{"issue":"2","key":"2175_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"S Peters","year":"2021","unstructured":"Peters\u00a0S, Felip\u00a0E, Dafni\u00a0U et al (2021) Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA\u2011B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase\u00a0II Trial (European Thoracic Oncology Platform 6\u201314). J\u00a0Thorac Oncol 16(2):278\u2013288. https:\/\/doi.org\/10.1016\/j.jtho.2020.10.129","journal-title":"J Thorac Oncol"},{"issue":"12","key":"2175_CR13","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1007\/s00259-021-05211-8","volume":"48","author":"C Eze","year":"2021","unstructured":"Eze\u00a0C, Schmidt-Hegemann\u00a0N\u2011S, Sawicki\u00a0LM et al (2021) PET\/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. Eur J Nucl Med Mol Imaging 48(12):3975\u20133989. https:\/\/doi.org\/10.1007\/s00259-021-05211-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2175_CR14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1053\/j.semnuclmed.2022.05.003","volume":"52","author":"F Manapov","year":"2022","unstructured":"Manapov\u00a0F, Eze\u00a0C, Holzgreve\u00a0A et\u00a0al (2022) PET\/CT for Target Delineation of Lung Cancer Before Radiation Therapy. Semin Nucl Med 52(6):673\u2013680. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.05.003","journal-title":"Semin Nucl Med"},{"issue":"1","key":"2175_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","volume":"127","author":"U Nestle","year":"2018","unstructured":"Nestle\u00a0U, de Ruysscher\u00a0D, Ricardi\u00a0U et al (2018) ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol 127(1):1\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2018.02.023","journal-title":"Radiother Oncol"},{"issue":"1","key":"2175_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2013.01.006","volume":"80","author":"TG Wiersma","year":"2013","unstructured":"Wiersma\u00a0TG, Dahele\u00a0M, Verbakel\u00a0WFAR et al (2013) Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer. Lung Cancer 80(1):62\u201367. https:\/\/doi.org\/10.1016\/j.lungcan.2013.01.006","journal-title":"Lung Cancer"},{"issue":"3","key":"2175_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3109\/0284186X.2013.819995","volume":"53","author":"EJF van Reij","year":"2014","unstructured":"van Reij\u00a0EJF, Dahele\u00a0M, van de Ven\u00a0PM et al (2014) Changes in non-surgical management of stage\u00a0III non-small cell lung cancer at a\u00a0single institution between 2003 and 2010. Acta Oncol 53(3):316\u2013323. https:\/\/doi.org\/10.3109\/0284186X.2013.819995","journal-title":"Acta Oncol"},{"issue":"1","key":"2175_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10637-021-01143-0","volume":"40","author":"J Taugner","year":"2022","unstructured":"Taugner\u00a0J, K\u00e4smann\u00a0L, Karin\u00a0M et al (2022) Planning target volume as a\u00a0predictor of disease progression in inoperable stage\u00a0III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and\/or sequential immune checkpoint inhibition. Invest New Drugs 40(1):163\u2013171. https:\/\/doi.org\/10.1007\/s10637-021-01143-0","journal-title":"Invest New Drugs"},{"key":"2175_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103035","author":"M Karin","year":"2020","unstructured":"Karin\u00a0M, Taugner\u00a0J, K\u00e4smann\u00a0L et al (2020) Association of Planning Target Volume with Patient Outcome in Inoperable Stage\u00a0III NSCLC Treated with Chemoradiotherapy: A\u00a0Comprehensive Single-Center Analysis. Cancers. https:\/\/doi.org\/10.3390\/cancers12103035","journal-title":"Cancers"},{"issue":"1","key":"2175_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s12885-019-5863-2","volume":"19","author":"E Dubaere","year":"2019","unstructured":"Dubaere\u00a0E, Goffaux\u00a0M, Wanet\u00a0M et al (2019) Long term outcome after 48\u202fGy stereotactic ablative body radiotherapy for peripheral stage\u00a0I non-small cell lung cancer. Bmc Cancer 19(1):639. https:\/\/doi.org\/10.1186\/s12885-019-5863-2","journal-title":"Bmc Cancer"},{"issue":"5","key":"2175_CR21","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.ijrobp.2019.12.027","volume":"106","author":"J Peng","year":"2020","unstructured":"Peng\u00a0J, Pond\u00a0G, Donovan\u00a0E et al (2020) A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage\u00a0III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 106(5):985\u2013992. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.12.027","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2175_CR22","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1120\/jacmp.v14i1.4110","volume":"14","author":"CE Merrow","year":"2012","unstructured":"Merrow\u00a0CE, Wang\u00a0IZ, Podgorsak\u00a0MB (2012) A dosimetric evaluation of VMAT for the treatment of non-small cell lung cancer. J\u00a0Applied Clin Med Phys 14(1):4110. https:\/\/doi.org\/10.1120\/jacmp.v14i1.4110","journal-title":"J Applied Clin Med Phys"},{"key":"2175_CR23","doi-asserted-by":"publisher","unstructured":"Flentje M, Huber RM, Engel-Riedel W et\u00a0al. (2016) GILT\u2014A randomised phase\u00a0III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage\u00a0III non-small cell lung cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft \u2026 [et al] 192(4): 216\u2013222. https:\/\/doi.org\/10.1007\/s00066-016-0941-8","DOI":"10.1007\/s00066-016-0941-8"},{"issue":"2","key":"2175_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jtho.2019.10.002","volume":"15","author":"JE Gray","year":"2020","unstructured":"Gray\u00a0JE, Villegas\u00a0A, Daniel\u00a0D et al (2020) Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage\u00a0III NSCLC-Update from PACIFIC. J\u00a0Thorac Oncol 15(2):288\u2013293. https:\/\/doi.org\/10.1016\/j.jtho.2019.10.002","journal-title":"J Thorac Oncol"},{"issue":"24","key":"2175_CR25","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia\u00a0SJ, Villegas\u00a0A, Daniel\u00a0D et\u00a0al (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage\u00a0III NSCLC. N\u00a0Engl J Med 379(24):2342\u20132350. https:\/\/doi.org\/10.1056\/NEJMoa1809697","journal-title":"N Engl J Med"},{"key":"2175_CR26","doi-asserted-by":"publisher","unstructured":"Durm GA, Jabbour SK, Althouse SK et al (2020) A phase\u00a02\u00a0trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage\u00a0III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179. Cancer 126(19): 4353\u20134361. https:\/\/doi.org\/10.1002\/cncr.33083","DOI":"10.1002\/cncr.33083"},{"issue":"1","key":"2175_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jrr\/rrac057","volume":"64","author":"N Kishi","year":"2023","unstructured":"Kishi\u00a0N, Matsuo\u00a0Y, Shintani\u00a0T et al (2023) Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage\u00a0III non-small cell lung cancer. JRR 64(1):142\u2013153. https:\/\/doi.org\/10.1093\/jrr\/rrac057","journal-title":"JRR"},{"key":"2175_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.radonc.2020.04.047","volume":"149","author":"M Offin","year":"2020","unstructured":"Offin\u00a0M, Shaverdian\u00a0N, Rimner\u00a0A et al (2020) Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage\u00a0III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiother Oncol 149:205\u2013211. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.047","journal-title":"Radiother Oncol"},{"key":"2175_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","volume":"146","author":"HA Jung","year":"2020","unstructured":"Jung\u00a0HA, Noh\u00a0JM, Sun\u00a0J\u2011M et al (2020) Real world data of durvalumab consolidation after chemoradiotherapy in stage\u00a0III non-small-cell lung cancer. Lung Cancer 146:23\u201329. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.035","journal-title":"Lung Cancer"},{"issue":"2","key":"2175_CR30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2020.03.25","volume":"9","author":"L K\u00e4smann","year":"2020","unstructured":"K\u00e4smann\u00a0L, Eze\u00a0C, Taugner\u00a0J et al (2020) Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage\u00a0III non-small cell lung cancer (NSCLC)\u2014a German radiation oncology survey. Transl Lung Cancer Res 9(2):288\u2013293. https:\/\/doi.org\/10.21037\/tlcr.2020.03.25","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"2175_CR31","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10637-021-01091-9","volume":"39","author":"J Taugner","year":"2021","unstructured":"Taugner\u00a0J, K\u00e4smann\u00a0L, Eze\u00a0C et al (2021) Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients. Invest New Drugs 39(4):1189\u20131196. https:\/\/doi.org\/10.1007\/s10637-021-01091-9","journal-title":"Invest New Drugs"},{"key":"2175_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071613","author":"J Taugner","year":"2021","unstructured":"Taugner\u00a0J, K\u00e4smann\u00a0L, Eze\u00a0C et al (2021) Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage\u00a0III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting. Cancers. https:\/\/doi.org\/10.3390\/cancers13071613","journal-title":"Cancers"},{"key":"2175_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04174-z","author":"B Fl\u00f6rsch","year":"2022","unstructured":"Fl\u00f6rsch\u00a0B, Taugner\u00a0J, K\u00e4smann\u00a0L et al (2022) Treatment patterns and prognosis of patients with inoperable stage\u00a0III NSCLC after completion of concurrent chemoradiotherapy\u00a0\u00b1 immune checkpoint inhibition: a\u00a0decade-long single-center historical analysis. J\u00a0Cancer Res Clin Oncol. https:\/\/doi.org\/10.1007\/s00432-022-04174-z","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"2175_CR34","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1097\/JTO.0b013e318267d032","volume":"7","author":"D Morgensztern","year":"2012","unstructured":"Morgensztern\u00a0D, Waqar\u00a0S, Subramanian\u00a0J et al (2012) Prognostic significance of tumor size in patients with stage\u00a0III non-small-cell lung cancer: a\u00a0surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003. J\u00a0Thorac Oncol 7(10):1479\u20131484. https:\/\/doi.org\/10.1097\/JTO.0b013e318267d032","journal-title":"J Thorac Oncol"},{"key":"2175_CR35","doi-asserted-by":"publisher","unstructured":"Nagasaka M, Abdallah N, Crosby M et\u00a0al. (2019) A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a\u00a0predictor of response to program death\u20111 (PD-1) inhibitors. Lung Cancer: Targets and Therapy 10: 95\u2013105. https:\/\/doi.org\/10.2147\/LCTT.S219886","DOI":"10.2147\/LCTT.S219886"},{"key":"2175_CR36","doi-asserted-by":"publisher","unstructured":"K\u00e4smann L, Niyazi M, Blanck O et\u00a0al. (2018) Pr\u00e4diktiver und prognostischer Wert des Tumorvolumens und seiner Ver\u00e4nderungen w\u00e4hrend radikaler Strahlentherapie beim nicht-kleinzelligen Bronchialkarzinom im Stadium\u00a0III : Ein systematischer Review (Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage\u00a0III non-small cell lung cancer : A\u00a0systematic review). Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft \u2026 [et al] 194(2): 79\u201390. https:\/\/doi.org\/10.1007\/s00066-017-1221-y","DOI":"10.1007\/s00066-017-1221-y"},{"key":"2175_CR37","doi-asserted-by":"publisher","unstructured":"Ostheimer C, M\u00e4urer M, Ebert N et\u00a0al. (2021) Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft\u00a0\u2026 [et al] 197(5): 385\u2013395. https:\/\/doi.org\/10.1007\/s00066-020-01727-4","DOI":"10.1007\/s00066-020-01727-4"},{"issue":"5","key":"2175_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.prro.2013.12.002","volume":"4","author":"S Garg","year":"2014","unstructured":"Garg\u00a0S, Gielda\u00a0BT, Kiel\u00a0K et al (2014) Patterns of locoregional failure in stage\u00a0III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol 4(5):342\u2013348. https:\/\/doi.org\/10.1016\/j.prro.2013.12.002","journal-title":"Pract Radiat Oncol"},{"issue":"5","key":"2175_CR39","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/1759-7714.12463","volume":"8","author":"H Imai","year":"2017","unstructured":"Imai\u00a0H, Kaira\u00a0K, Minato\u00a0K (2017) Clinical significance of post-progression survival in lung cancer. Thorac Cancer 8(5):379\u2013386. https:\/\/doi.org\/10.1111\/1759-7714.12463","journal-title":"Thorac Cancer"},{"issue":"11","key":"2175_CR40","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JOP.19.00357","volume":"15","author":"V Ernani","year":"2019","unstructured":"Ernani\u00a0V, Stinchcombe\u00a0TE (2019) Management of Brain Metastases in Non-Small-Cell Lung Cancer. JOP 15(11):563\u2013570. https:\/\/doi.org\/10.1200\/JOP.19.00357","journal-title":"JOP"},{"key":"2175_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2023.04.008","author":"L Delasos","year":"2023","unstructured":"Delasos\u00a0L, Wei\u00a0W, Hassan\u00a0KA et al (2023) Clinical outcomes with pembrolizumab-based therapies in recurrent\/refractory NSCLC after chemoradiation and consolidative durvalumab. Clin Lung Cancer. https:\/\/doi.org\/10.1016\/j.cllc.2023.04.008","journal-title":"Clin Lung Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02175-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02175-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02175-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:04:22Z","timestamp":1718813062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02175-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2175"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02175-6","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.\u00a0Tufman receives travel support from Pfizer and Amgen. C.\u00a0Belka eceives grants or contracts from any entity but not related to this manuscript from Viewray, Brainlab and ELEKTA. C.\u00a0Belka receives honoraria from BMS, ROCHE, MERCK, Astrazeneca and Viewray. C.\u00a0Belka receives support for attending meetings and\/or travel from BMS, ROCHE, MERCK, Astrazeneca and Viewray. C.\u00a0Belka receives BMS, ROCHE, MERCK, Astrazeneca and Viewray. C.\u00a0Belka serves in a\u00a0fiduciary role in the ESTRO. C.\u00a0Eze receives grants or contracts from any entity but not related to this manuscript from German Cancer Aid. C.\u00a0Eze receives consulting fees from Novartis. C.\u00a0Eze receives support for attending meetings and\/or travel from Novartis. F.\u00a0Manapov receives an unrestricted Research Institutional Grant from AstraZeneca. F.\u00a0Manapov receives honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta and Brainlab. F.\u00a0Manapov serves in the advisory board of AstraZeneca, Novartis. L.\u00a0K\u00e4smann receives honoraria from AMGEN. N.\u00a0Reinmuth reports receiving honoraria for speaker activities and participation in advisory boards for AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, and Takeda. K.\u00a0Hofstetter, J.\u00a0Taugner, S.\u00a0Mansoorian, B.\u00a0Fl\u00f6rsch and T.\u00a0Duell declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients gave express written informed consent. This retrospective analysis is in compliance with the principles of the Declaration of Helsinki and its subsequent amendments. This work was approved by the Ethics Committee of the Ludwig Maximilian University of Munich (reference number: 17-230).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}